In contrast, driver mutations’ (JAK2, CALR, or MPL) allele frequencies decreased upon ruxolitinib exposure in five out of six patients, suggesting that RAS-mutated clones might not always be present within the MPN driver clone (Fig. 3A). The gene discussed is MPL; the disease is myeloproliferative neoplasm.